The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway

British Journal of Haematology

Volumn 151, Issue 2, 2010, Pages 185-188

  Best, O Giles ^a   Singh, Nisha ^a   Forsyth, Cecily ^a,b   Mulligan, Stephen P ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Royal North Shore Hospital ^*  (Australia)

Author keywords

cancer; Chronic Lymphocytic Leukaemia; CLL drug sensitivity; new drugs for leukaemia; TP53

Indexed keywords

ATM PROTEIN; CD38 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOXANTRONE; PREDNISOLONE; PROTEIN KINASE ZAP 70; PROTEIN P53; RITUXIMAB; SNX 7081; TANESPIMYCIN; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, P53; HEMATOLOGIC NEOPLASMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77957374909     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08348.x     Document Type: Article

References (10)

1. Aguilar-Santelises, M., Magnusson, K.P., Wiman, K.G., Mellstedt, H. Jondal, M. (1994) Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression. International Journal of Cancer, 58, 474 479.
2. Best, O.G., Gardiner, A.C., Majid, A., Walewska, R., Austen, B., Skowronska, A., Ibbotson, R., Stankovic, T., Dyer, M.J. Oscier, D.G. (2008) A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia, 22, 1456 1459.
3. zum Büschenfelde, C.M., Wagner, M., Lutzny, G., Oelsner, M., Feuerstacke, Y., Decker, T., Bogner, C., Peschel, C. Ringshausen, I. (2010) Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia, 24, 141 152.
4. Castro, J.E., Prada, C.E., Loria, O., Kamal, A., Chen, L., Burrows, F.J. Kipps, T.J. (2005) ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood, 106, 2506 2512.
5. Cysyk, R.L., Parker, R.J., Barchi, Jr., J.J., Steeg, P.S., Hartman, N.R. Strong, J.M. (2006) Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chemical Research in Toxicology, 19, 376 381.
6. Jin, L., Xiao, C.L., Lu, C.H., Xia, M., Xing, G.W., Xiong, S., Liu, Q.Y., Liu, H., Li, Y.C., Ge, F., Wang, Q.D., He, Q.Y. Wang, Y.F. (2009) Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice. FEBS Letters, 583, 1859 1866.
7. Jones, D.T., Addison, E., North, J.M., Lowdell, M.W., Hoffbrand, A.V., Mehta, A.B., Ganeshaguru, K., Folarin, N.I. Wickremasinghe, R.G. (2004) Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood, 103, 1855 1861.
8. Lin, K., Rockliffe, N., Johnson, G.G., Sherrington, P.D. Pettitt, A.R. (2008) Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene, 27, 2445 2455.
9. Okawa, Y., Hideshima, T., Steed, P., Vallet, S., Hall, S., Huang, K., Rice, J., Barabasz, A., Foley, B., Ikeda, H., Raje, N., Kiziltepe, T., Yasui, H., Enatsu, S. Anderson, K.C. (2009) SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood, 113, 846 855.
10. Orchard, J.A., Ibbotson, R.E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P.W., Hamblin, T.J., Staudt, L.M. Oscier, D.G. (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet, 363, 105 111.